The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients.

Lamberts SW, Oosterom R, Neufeld M, del Pozo E

The Journal of clinical endocrinology and metabolism1 Jun 1985Cited by 95 (Europe PMC)

PMID2860119DOI10.1210/jcem-60-6-1161PepBankPUB-02860119

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialEfficacy outcome
SMS reduced GH in seven of eight acromegalic patients, from 30 +/- 5 to 10.7 +/- 4 micrograms/l during 1-10 h after administration.
In plain wordsSMS reduced growth hormone in seven of eight acromegalic patients during 1-10 h after administration.
Peptide
Octreotide
Outcome
DecreaseGrowth hormone
Study
n = 8
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
50 micrograms · subcutaneousAs given in this study (human).
Measurements
Serum GH
30 micrograms/l
initial level, +/- SE 5
Serum GH
10.7 micrograms/l
average 1-10 h after SMS, +/- SE 4
Patients with decreased GH
7 patients
acromegaly
P value
< 0.001
GH decrease
Source sentences
Summary
GH significantly (P less than 0.001) decreased in seven of eight acromegalic patients from 30 +/- 5 (+/- SE) to an average of 10.7 +/- 4 micrograms/l from 1-10 h after drug administration.
2 context sentences(design, population, supporting numbers)
Summary · context
The acute effect of the somatostatin analog SMS 201-995 (SMS) was investigated in eight acromegalic patients.
Summary · context
After a control day, 50 micrograms SMS were injected sc, and plasma GH and insulin and blood glucose levels were measured at multiple intervals for 24 h.
Report a problemFND-0286011901
02HumanNon-randomized trialEfficacy outcome
SMS did not alter circulating GH in one acromegalic patient.
In plain wordsSMS did not change circulating growth hormone in one acromegalic patient.
Peptide
Octreotide
Outcome
No significant changeGH in a nonresponding patient
Study
n = 1
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
50 micrograms · subcutaneousAs given in this study (human).
Source sentences
Summary
Circulating GH was not altered by SMS or the dopamine agonist mesulergine in one patient
2 context sentences(design, population, supporting numbers)
Summary · context
The acute effect of the somatostatin analog SMS 201-995 (SMS) was investigated in eight acromegalic patients.
Summary · context
After a control day, 50 micrograms SMS were injected sc, and plasma GH and insulin and blood glucose levels were measured at multiple intervals for 24 h.
Report a problemFND-0286011905
03HumanNon-randomized trialEfficacy outcome
No rebound GH hypersecretion occurred after SMS in acromegalic patients.
In plain wordsNo rebound growth hormone excess occurred after SMS in acromegalic patients.
Peptide
Octreotide
Outcome
Not applicableRebound GH hypersecretion
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
50 micrograms · subcutaneousAs given in this study (human).
Source sentences
Summary
No rebound effect occurred.
3 context sentences(design, population, supporting numbers)
Summary · context
GH significantly (P less than 0.001) decreased in seven of eight acromegalic patients from 30 +/- 5 (+/- SE) to an average of 10.7 +/- 4 micrograms/l from 1-10 h after drug administration.
Summary · context
The acute effect of the somatostatin analog SMS 201-995 (SMS) was investigated in eight acromegalic patients.
Summary · context
After a control day, 50 micrograms SMS were injected sc, and plasma GH and insulin and blood glucose levels were measured at multiple intervals for 24 h.
Report a problemFND-0286011902
04HumanNon-randomized trialEfficacy outcome
In acromegalic patients, postprandial glucose was significantly higher 2-4 h after SMS than on the control day.
In plain wordsIn acromegalic patients, SMS increased blood glucose after meals compared with the control day.
Peptide
Octreotide
Outcome
IncreasePostprandial blood glucose
Study
n: not reported in source
Comparator
Control day
Outcome group
Glycemic control · Metabolic and weight
Studied dose
50 micrograms · subcutaneousAs given in this study (human).
Measurements
P value
< 0.01
postprandial glucose 2-4 h after SMS versus control day
Source sentences
Summary
Postprandial blood glucose levels were significantly (P less than 0.01) higher between 2 and 4 h after SMS treatment compared with control day values, and there was a substantial reduction in insulin secretion, as estimated by the area under the curve (P less than 0.01), during the first 3 h after SMS administration.
2 context sentences(design, population, supporting numbers)
Summary · context
The acute effect of the somatostatin analog SMS 201-995 (SMS) was investigated in eight acromegalic patients.
Summary · context
After a control day, 50 micrograms SMS were injected sc, and plasma GH and insulin and blood glucose levels were measured at multiple intervals for 24 h.
Report a problemFND-0286011903
05HumanNon-randomized trialEfficacy outcome
In acromegalic patients, SMS significantly reduced insulin secretion AUC during the first 3 h after administration.
In plain wordsIn acromegalic patients, SMS reduced insulin secretion during the first 3 h after administration.
Peptide
Octreotide
Outcome
DecreaseInsulin secretion AUC
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
50 micrograms · subcutaneousAs given in this study (human).
Measurements
P value
< 0.01
insulin secretion AUC, first 3 h after SMS
Source sentences
Summary
Postprandial blood glucose levels were significantly (P less than 0.01) higher between 2 and 4 h after SMS treatment compared with control day values, and there was a substantial reduction in insulin secretion, as estimated by the area under the curve (P less than 0.01), during the first 3 h after SMS administration.
2 context sentences(design, population, supporting numbers)
Summary · context
The acute effect of the somatostatin analog SMS 201-995 (SMS) was investigated in eight acromegalic patients.
Summary · context
After a control day, 50 micrograms SMS were injected sc, and plasma GH and insulin and blood glucose levels were measured at multiple intervals for 24 h.
Report a problemFND-0286011904

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.